Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with potential anticancer effect, but innate and adaptive TRAIL resistance in majority of cancers limit its clinical application. Karyopherin β1 (KPNB1) inhibition in cancer cells has been reported to abrogate the nuclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhi-Chuan, Liu, Ji-Wei, Yang, Can, Li, Ming-Jie, Wu, Rong-Jie, Xiong, Zhi-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370806/
https://www.ncbi.nlm.nih.gov/pubmed/30742128
http://dx.doi.org/10.1038/s41419-019-1383-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370806/
https://www.ncbi.nlm.nih.gov/pubmed/30742128
http://dx.doi.org/10.1038/s41419-019-1383-x

Ejemplares similares